Eliem Therapeutics Inc
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Eliem Therapeutics Inc (ELYM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.003x
Based on the latest financial reports, Eliem Therapeutics Inc (ELYM) has a cash flow conversion efficiency ratio of -0.003x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-667.00K) by net assets ($222.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eliem Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Eliem Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eliem Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eliem Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emerging Display Technologies Corp
TW:3038
|
0.078x |
|
F3 Uranium Corp.
OTCQB:FUUFF
|
-0.019x |
|
Elektrotim SA
WAR:ELT
|
0.047x |
|
Bastide Le Confort Médical SA
PA:BLC
|
0.479x |
|
Forest Water Environmental Eng Co Ltd
TW:8473
|
0.072x |
|
FOCUSRITE PLC LS -001
F:0FO
|
N/A |
|
Indoco Remedies Limited
NSE:INDOCO
|
0.162x |
|
Amulaire Thermal Technology
TW:2241
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Eliem Therapeutics Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Eliem Therapeutics Inc from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |